NASDAQ:CRDF

Cardiff Oncology Stock Insider Trading

Healthcare > Biotechnology

Buy CRDF

*Your capital is at risk

$1.40

-0.110 (-7.28%)

At Close: Jun 03, 2026

Cardiff Oncology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 14.6M and sold 0 CRDF shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	14.6M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 12, 2024 Buy	Common Stock P-Purchase	Tannenbaum Renee P Director	Director	10 000 Value: $34.2K
Dec 11, 2024 Buy	Common Stock P-Purchase	Pace Gary W Director	Director	11 500 Value: $29.9K
Dec 11, 2024 Buy	Common Stock P-Purchase	Pace Gary W Director	Director	350 115 Value: $910.3K
Dec 11, 2024 Buy	Common Stock P-Purchase	Pace Gary W Director	Director	350 115 Value: $910.3K
Dec 11, 2024 Buy	Common Stock P-Purchase	Pace Gary W Director	Director	11 500 Value: $29.9K
Jun 27, 2024 Buy	Stock Options A-Award	White Lale Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Tannenbaum Renee P Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Mohindru Mani Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Pace Gary W Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Armitage James O Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Markin Rodney S Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Markin Rodney S Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Armitage James O Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Pace Gary W Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Mohindru Mani Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	Tannenbaum Renee P Director	Director	29 700 Value: $69.2K
Jun 27, 2024 Buy	Stock Options A-Award	White Lale Director	Director	29 700 Value: $69.2K
Mar 07, 2024 Buy	Stock Options A-Award	Levine James E. Chief Financial Officer	C-Suite Officer	205 008 Value: $719.6K
Mar 07, 2024 Buy	Stock Options A-Award	Kabbinavar Fairooz Chief Medical Officer	Officer	205 008 Value: $719.6K
Mar 07, 2024 Buy	Stock Options A-Award	Smeal Tod Chief Scientific Officer	Officer	205 008 Value: $719.6K
Mar 07, 2024 Buy	Stock Options A-Award	Erlander Mark Chief Executive Officer	CEO / President	510 000 Value: $1.79M
Mar 07, 2024 Buy	Stock Options A-Award	Erlander Mark Chief Executive Officer	CEO / President	510 000 Value: $1.79M
Mar 07, 2024 Buy	Stock Options A-Award	Smeal Tod Chief Scientific Officer	Officer	205 008 Value: $719.6K
Mar 07, 2024 Buy	Stock Options A-Award	Kabbinavar Fairooz Chief Medical Officer	Officer	205 008 Value: $719.6K
Mar 07, 2024 Buy	Stock Options A-Award	Levine James E. Chief Financial Officer	C-Suite Officer	205 008 Value: $719.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CARDIFF ONCOLOGY INC.

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...

Read Full Profile Here